Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy

BACKGROUND AND PURPOSE: We investigated the locoregional effect of trastuzumab, and determined whether patients with human epidermal growth factor receptor (HER)2-positive breast cancer (BC) treated with trastuzumab could achieve comparable efficacy to that of patients with HER2-negative BC. MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Guang-Yi, Jing, Hao, Wang, Shu-Lian, Song, Yong-Wen, Jin, Jing, Fang, Hui, Liu, Yue-Ping, Ren, Hua, Tang, Yu, Zhao, Xu-Ran, Song, Yu-Chun, Chen, Si-Ye, Yang, Zhuan-Bo, Chen, Bo, Tang, Yuan, Li, Ning, Lu, Ning-Ning, Qi, Shu-Nan, Yang, Yong, Li, Ye-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871908/
https://www.ncbi.nlm.nih.gov/pubmed/33575216
http://dx.doi.org/10.3389/fonc.2020.605750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871908/
https://www.ncbi.nlm.nih.gov/pubmed/33575216
http://dx.doi.org/10.3389/fonc.2020.605750

Ejemplares similares